Endocrinology

Conditions: Diabetes Mellitus; Hypertension; Hyperlipidemia
Interventions: Device: Pre-filled trays
Sponsors: University of Pennsylvania; TowerView Health
Completed

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

Conditions: Pancreatic Cancer; Liver Cancer (Locally Advanced or Metastatic); Pancreatic Cancer Non-resectable; Pancreatic Cancer Stage III; Pancreatic Cancer Stage IV; Liver Cancer Stage IV; Liver Cancer Stage IIIa; Liver Cancer Stage IIIb; Liver Cancer Stage IIIc
Interventions: Device: EUS-Guided MWA Device
Sponsors: Banner Health; Creo Medical Limited; CreoMed, Inc.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

Conditions: Congenital Adrenal Hyperplasia
Interventions: Drug: Chronocort®; Drug: Standard Care
Sponsors: Neurocrine UK Limited; National Institutes of Health (NIH)
Withdrawn

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

Conditions: Diabetes Mellitus, Type 2
Interventions: Drug: CagriSema
Sponsors: Novo Nordisk A/S
Not yet **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

Conditions: Hormone Receptor Positive Early Breast Cancer
Interventions: Drug: US-sourced oral Femara® + Letrozole SIE; Drug: EU sourced oral Femara® + Letrozole SIE
Sponsors: Rovi Pharmaceuticals Laboratories
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

Conditions: Neoplasms (Cancer / Tumors); Colorectal Neoplasms; Lung Neoplasms; Endometrial Neoplasms; Breast Neoplasms; Pancreatic Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Glioma; Ovarian Neoplasms; Stomach Neoplasms
Sponsors: Harvard Medical School (HMS and HSDM)
Not yet **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

Conditions: Diabetic Kidney Disease (DKD)
Interventions: Drug: ALN-ANG3; Drug: Evinacumab; Drug: Placebo
Sponsors: Regeneron Pharmaceuticals
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

Conditions: Endometrial Neoplasms; Ovarian Neoplasms; Soft Tissue Sarcoma (STS); Glioblastoma
Interventions: Drug: AL58805; Drug: AL3818; Drug: Temozolomide (TMZ); Drug: CCNU
Sponsors: Advenchen Pharmaceuticals, LLC.
Not yet **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

Conditions: Diabetic Macular Edema (DME)
Interventions: Drug: Oral BGE-102; Drug: Oral Placebo Matching BGE-102; Drug: Anti-VEGF; Other: Sham
Sponsors: BioAge Labs, Inc.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

Conditions: Primary Hyperparathyroidism
Interventions: Other: NIRAF-camera
Sponsors: The Cleveland Clinic
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.